Romero, Rodrigo https://orcid.org/0000-0002-9388-8306
Chu, Tinyi https://orcid.org/0000-0003-3369-6692
González Robles, Tania J. https://orcid.org/0000-0001-9292-382X
Smith, Perianne
Xie, Yubin https://orcid.org/0000-0003-2542-2544
Kaur, Harmanpreet
Yoder, Sara
Zhao, Huiyong
Mao, Chenyi
Kang, Wenfei
Pulina, Maria V.
Lawrence, Kayla E.
Gopalan, Anuradha
Zaidi, Samir
Yoo, Kwangmin
Choi, Jungmin https://orcid.org/0000-0002-8614-0973
Fan, Ning
Gerstner, Olivia
Karthaus, Wouter R.
DeStanchina, Elisa
Ruggles, Kelly V. https://orcid.org/0000-0002-0152-0863
Westcott, Peter M. K. https://orcid.org/0000-0001-9436-4857
Chaligné, Ronan https://orcid.org/0000-0003-4332-3291
Pe’er, Dana https://orcid.org/0000-0002-9259-8817
Sawyers, Charles L. https://orcid.org/0000-0003-4955-6475
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA193837, CA092629, CA224079, CA155169, CA008748, CA274492, U54CA209975, CA282978)
Charles H. Revson Foundation (22-23)
Damon Runyon Cancer Research Foundation (DRQ: 10-21)
Cycle for Survival, Marie-Josée and Henry R. Kravis Center for Molecular Oncology and the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center.
Burroughs Wellcome Fund
Article History
Received: 12 September 2023
Accepted: 6 September 2024
First Online: 11 October 2024
Competing interests
: C.L.S. is on the board of directors of Novartis, is a cofounder of ORIC Pharmaceuticals and is a co-inventor of the prostate cancer drugs enzalutamide and apalutamide, covered by US patents 7,709,517; 8,183,274; 9,126,941; 8,445,507; 8,802,689; and 9,388,159 filed by the University of California. C.L.S. is on the scientific advisory boards for the following biotechnology companies: Beigene, Blueprint Medicines, Column Group, Foghorn, Housey Pharma, Nextech, PMV Pharma and ORIC. D.P. is on the scientific advisory board of Insitro. The other authors declare no competing interests.